Browsing: takes

Yangsen Li (left), chief executive officer of LCH Development and developer of The Pinnacle, in conversation with Miller as the two look at a scale model of the luxury residences under construction

Dibrugarh: Assam Medical College and Hospital (AMCH), Dibrugarh, has started treatment for 15 patients suffering from rare diseases after being designated as a Centre of Excellence in Rare Diseases, Chief Minister Himanta Biswa Sarma said on Saturday

Sixteen days into a 21-day, 500-mile run around Jamaica, Michael De Roeck is putting his endurance to the test to raise funds for the young people served by Freedom Skatepark. De Roeck, a trustee of the Freedom Skatepark Foundation, began the Freedom Skatepark 500 on August 7 at the organisation’s Bull Bay facility to raise…

N.Y. — Dr. John Evanko has worked across healthcare for more than 30 years. Leaders at Richmond University Medical Center hope he can lead the hospital into its chapter

Arizona Pastor Mark Driscoll recently discussed a controversial issue, one that is frequently talked about today: weight. Specifically, he stated whether or not, in his view, someone who is obese should be disqualified from being a pastor and leading a church. 

CAMP ATTERBURY, Ind. — More than 4,700 U.S. and allied service members converged at Camp Atterbury and Muscatatuck Urban Training Center July 18 to Aug. 1 to test new capabilities and build lethal combat power during CRX 26-02

Pila Pharma has received regulatory approval from the European Medicines Agency to conduct PP-CT04, a randomised, double-blind, placebo-controlled trial evaluating XEN-D0501 in people living with obesity over 12 weeks. The trial will explore doses up to four times higher than those studied previously and over significantly longer duration. BioStock contacted CEO Gustav Hanghøj Gram to…

Finding music for a run sounds easy until you actually try. Your favorite playlist might work perfectly for a relaxed jog, then feel completely wrong when you’re pushing through intervals. And after hearing the same handful of workout songs for the hundredth time, even a good playlist can start feeling painfully predictable

It’s already been a full commercial quarter since the April approval of Eli Lilly’s weight loss pill Foundayo—which means analysts now have around three months’ worth of sales data to see how the oral obesity battle is shaping up

Novo Nordisk has registered a first-in-human Phase I study of previously undisclosed obesity candidate NNC0721-8060, with a 142-participant program that will evaluate weight loss and include semaglutide alongside placebo despite the company keeping the asset’s target and modality under wraps